NewTimeSpace News: Transport International announced on 13 July that the Group expects its underlying profit for the six months ended 30 June 2026 to decrease by approximately 45% to 55% compared with HK$285 million recorded in the same period of 2025.
NewTimeSpace News: SHANGHAI IND H (00363.HK) announced on 13 July that construction has kicked off for the expansion project of G50 Shanghai-Chongqing Expressway (Shanghai Section). The project stretches 32.6 kilometres and involves upgrading the existing dual 4–6 lanes to dual 8 lanes, with estimated total investment surpassing RMB5.3 billion. Classified as a key municipal infrastructure project of Shanghai, construction will adopt the mode of "operation alongside construction".
NewTimeSpace News: ZHAOKE OPHTH-B (06622.HK) announced on 13 July that it has completed the acquisition of global rights to NVK002 (Atropine Sulfate Eye Drops), gaining full control over the development and commercialisation of the paediatric myopia treatment. Under the deal, a perpetual royalty-free exclusive licence for development and commercialisation in the US is granted to the vendor. The Group previously held rights for Greater China, South Korea and certain Southeast Asian territories. The Company cautions there is no guarantee of successful development or commercial launch of the asset.
NewTimeSpace News: Modern Land (01107.HK) announced on 13 July that it has received resumption guidance issued by HKEX dated 8 July 2026. Conditions include publishing all outstanding financial results and addressing audit adjustments, demonstrating compliance with Listing Rule 13.24, appointing an independent internal control consultant to verify rectified control deficiencies and adequate internal controls, and disclosing all material information to the market. Shares have been suspended since 1 April 2026. The delisting deadline under Listing Rule 6.01A(1) falls on 30 September 2027. The Company is taking appropriate steps to satisfy the resumption conditions. Trading suspension will continue until further notice.
NewTimeSpace News: Leads Biolabs-B(09887.HK) announced on 13 July that six research outcomes have been accepted for presentation at ESMO Congress 2026, comprising two Proffered Paper oral presentations, four poster displays and Late-Breaking Abstract (LBA) qualification, covering extrapulmonary neuroendocrine carcinoma (EP-NEC), biliary tract cancer and relapsed/refractory multiple myeloma. The Company stated the selections reflect international recognition of its clinical data and pipeline value and demonstrate sustained innovation capabilities in tumour immunotherapy. Previously, a study of VELIXIN™ for first-line non-small cell lung cancer was selected for oral presentation at WCLC. Investors are reminded of uncertainties relating to product development and commercialisation.
NewTimeSpace News: On 13 July 2026, BIDU-SW(09888.HK) edged lower in afternoon trading. As of 15:27, the stock traded at HK$114.50, down 0.78%. Baidu’s full-stack AI product matrix covering chips, cloud, foundation models and AI agents will launch new upgrades at WAIC, showcasing the large-scale commercial implementation of Baidu AI spanning underlying technological innovations, industrial scenarios and consumer applications.
NewTimeSpace (newtimespace.com) reported that on July 13, 2026, Hong Kong semiconductor stocks fluctuated lower, with SMIC (00981.HK) rallying then pulling back. As of 14:22, the stock was quoted at HKD 77.400, down 2.82%.
NewTimeSpace (newtimespace.com) reported that on July 13, 2026, the humanoid robot theme weakened significantly, with UBTECH (09880.HK) extending its decline. As of 13:45, the stock was quoted at HKD 81.250, down 4.47%.
NewTimeSpace News: Tastegourmet GP (08371.HK) announced that its wholly-owned subsidiary has entered into a new tenancy agreement to launch a new Golden Dragon Teppanyaki restaurant in Taikoo Shing, Hong Kong. The four-year lease took effect on 1 July 2026, and the new outlet is scheduled to commence operation in the third quarter of 2026, marking the Group’s fourth Golden Dragon Teppanyaki restaurant in Hong Kong.
NewTimeSpace News: Road King Infrastructure (01098.HK) announced that upon expiry of the Early Bird RSA Fee Deadline on 10 July 2026, holders representing more than 60% of the aggregate principal amount of the Existing Notes and Existing Perpetual Securities have acceded to the Restructuring Support Agreement (RSA). Remaining holders are reminded that the General RSA Fee Deadline is 5:00 p.m., Hong Kong Time, on 24 July 2026.
NewTimeSpace News: SSY GROUP (02005.HK) announced that Baloxavir Marboxil active pharmaceutical ingredient (API) of the Group has been approved and registered by NMPA for use in marketed formulations, making the Company the third domestic enterprise to obtain the approval. Baloxavir Marboxil is mainly indicated for the treatment of influenza A and B viruses.
NewTimeSpace (newtimespace.com) News, On July 13, 2026, Hong Kong large model concept stocks diverged in morning trading, with stocks such as Zhipu (2513.HK), Mininglamp Technology (2718.HK), and Kuaishou (1024.HK) leading the gains.As of 09:48, Zhipu (2513.HK) was quoted at HK$1,833.000, achieving an intraday surge of 11.77% and leading the gains in the large model concept stock theme.
NewTimeSpace News: ABBISKO-B (02256.HK) announced on 13 July that ABSK211, an oral pan-KRAS inhibitor, has obtained FDA clearance for Phase I clinical development in advanced solid tumours with KRAS alterations. Preclinical data demonstrate broad potency against multiple KRAS variants and synergistic anti-tumour efficacy in combination regimens. The candidate has secured IND approvals in both China and the U.S. The Company reminds investors of uncertainties in drug development and approval processes.
NewTimeSpace News: Longbio-B (01779.HK) announced on 13 July that LP-003, an in-house developed anti-IgE antibody, has obtained clearance from the U.S. FDA to launch clinical trials for peanut allergy. The global food allergy patient population is projected to reach 457 million by 2030. In China, the Company has secured IND approvals or initiated clinical studies of LP-003 across multiple allergic indications. The Company cautions uncertainties exist regarding successful development and commercialisation of the asset.
NewTimeSpace News: INSILICO (03696.HK) announced on 13 July that the Group has entered into a new strategic cooperation for central nervous system drug research and development with Cosmo Pharmaceutical Holdings Limited. Leveraging INSILICO’s AI platform and Cosmo’s profound disease expertise, both parties will jointly advance innovative drug development. INSILICO is eligible to receive milestone payments of up to approximately RMB1.2 billion in aggregate, plus net sales royalties. The Company reminded investors that forward-looking statements are not guaranteed to materialise and shareholders should exercise caution when trading shares.
NewTimeSpace News: GUOEN HOLDINGS (08121.HK) plans to conduct a rights issue on the basis of "1 for 4", with estimated net proceeds of HKD 40.4 million.
